Use cases
One signature, real decisions.
For pharma, biotech, animal health and cosmetics. Pick a question.
Stratify the patients in a trial
higher odds of reaching approval when patients are selected by biomarker2
Programmes approved per 100 entering phase I
One diagnosis can hide several biologies. A trial that does not tell them apart dilutes the effect of the molecule.
Enrolling the patients who carry the targeted mechanism gives the molecule a real chance to show its effect.
- Biological inclusion criterion: one score per patient.
- Enrichment of cohorts and smaller sample sizes.
- Companion diagnostic: the signature becomes the test sold with the drug.
Mode of action, alone or in synergy
A molecule acts on far more than its target. We read its full molecular footprint and place it against thousands of diseases and treatments.
For a combination: is the effect the sum of both, or does the mixture create a biology of its own?
- Mode-of-action map: activated and repressed pathways.
- Synergy analysis: additive versus combination-specific effects.
- Positioning against known treatments.
- Pharmacodynamic markers, candidates.
New mechanisms, new claims
Crossing thousands of contrasts reveals links nobody has named: a pathway shared by two diseases, a subgroup defined by its biology.
In pharma, a new indication. In animal health and cosmetics, a new claim backed by a measurement.
- Mechanistic hypotheses ranked by strength of evidence.
- Repositioning: where your molecule reverses the disease.
- Endotypes that are biologically homogeneous.
- Intellectual property foundation.
Read the response to treatment
The clinical endpoint comes late; biology moves first. A response signature shows whether the molecule reaches its target, how strongly, and in whom.
- Target engagement measured in blood, to adjust a dose.
- Early response within the first weeks.
- Disease activity in relapsing conditions.
Find the responders in a negative trial
A trial can miss its primary endpoint and still contain a subgroup that clearly responded. If that subgroup is defined by its biology, it can found the next trial.
- Blinded analysis on biobanked samples.
- Subgroup definition and its selection criterion.
- Next phase with an enriched population.
Unlock your omics data
Many companies hold transcriptomic, proteomic or microbiome data they cannot use beyond the original study. We give it new reach.
- Audit and harmonisation, any format.
- Context against thousands of contrasts.
- Deliverables: signatures, mechanisms, claim support.
- Confidentiality: data analysed in coded form.
Going further
Every question can become a project. See our offer.
Sources